TITLE:
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

CONDITION:
Alzheimer's Disease

INTERVENTION:
ABT-089

SUMMARY:

      The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of
      ABT-089 BID to placebo in adults with Alzheimer's disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 50 Years to 85 Years
Criteria:

        INCLUSION CRITERIA:

          -  Current diagnosis of probable Alzheimer's disease.

          -  ADAS-cog score of at least 12 and MMSE score of 10 to 26.

          -  Non-smoker

          -  Must have legally authorized representative and a reliable caregiver. The caregiver
             and legally authorized representative may be the same person.

          -  Fluent in English.

        EXCLUSION CRITERIA:

          -  Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in
             the last 6 weeks.

          -  Has clinically significant or uncontrolled medical condition other than Alzheimer's
             disease.

          -  Nursing home resident.
      
